An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Open accessThe DOI matches its Crossref record.
Abstract
Female patients (n = 20) with osteoporosis, aged 66 +/- 5 yr were studied during a 24-h infusion of parathyroid hormone (PTH [1-34]) at a rate of 0.5 IU equivalents/kg.h, and then during a 28-d period of subcutaneous injections, at a dose of 800 IU equivalents per day. Thereafter half the patients received subcutaneous injections of calcitonin, 75 U/d for 42 d, and all patients were followed to the end of a 90-d cycle. Biochemical markers of bone formation (serum alkaline phosphatase, osteocalcin, and the carboxy-terminal extension peptide of pro-collagen 1) and bone resorption (fasting urine calcium, hydroxyproline, and deoxypyridinoline) were compared during treatment by the intravenous and subcutaneous route of PTH administration, and subsequently during calcitonin therapy. During intravenous PTH infusion there were significant reductions in all three bone formation markers, despite expected rises in urinary calcium and hydroxyproline. By contrast, the circulating markers of bone formation increased rapidly by > 100% of baseline values during daily PTH injections (P < 0.001). Significant increases in bone resorption markers were only seen at the end of the 28 d of injections, but were < 100% over baseline values, (P < 0.05). Quantitative bone histomorphometry from biopsies obtained after 28 d of PTH treatment confirmed that bone formation at both the cellular and tissue levels were two to five times higher than similar indices measured in a control group of biopsies from untreated osteoporotic women. Subsequent treatment of these patients with calcitonin showed no significant changes in the biochemical markers of bone formation and only a modest attenuation of bone resorption. Thus, PTH infusion may inhibit bone formation, as judged by circulating biochemical markers, whereas daily injections confirm the potent anabolic actions of the hormone. Sequential calcitonin therapy does not appear to act synergistically with PTH in cyclical therapeutic protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lindsay, R., Nieves, J., Formica, C., Henneman, E., Woelfert, L., Shen, V., Dempster, D., & Cosman, F. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02342-8 · Cited by 749
Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., et al. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0006 · Cited by 718
Self-citationAnabolic Actions of Parathyroid Hormone on Bone*
DEMPSTER, D. W., COSMAN, F., PARISIEN, M., SHEN, V., & LINDSAY, R. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-6-690 · Cited by 717
Borer, K. T. (2005) · Sports Medicine · doi:10.2165/00007256-200535090-00004 · Cited by 373
Body, J.-J., Gaich, G. A., Scheele, W. H., Kulkarni, P. M., Miller, P. D., Peretz, A., Dore, R. K., Correa-Rotter, R., Papaioannou, A., Cumming, D. C., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020334 · Cited by 365
Self-citationKurland, E. S., Cosman, F., McMahon, D. J., Rosen, C. J., Lindsay, R., & Bilezikian, J. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6818 · Cited by 360
Enhancement of Bone Mass in Osteoporotic Women with Parathyroid Hormone followed by Alendronate1
Rittmaster, R. S., Bolognese, M., Ettinger, M. P., Hanley, D. A., Hodsman, A. B., Kendler, D. L., & Rosen, C. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6614 · Cited by 307
Self-citationLindsay, R., Cosman, F., Zhou, H., Bostrom, M. P., Shen, V. W., Cruz, J. D., Nieves, J. W., & Dempster, D. W. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051109 · Cited by 277
Nakamura, T., Sugimoto, T., Nakano, T., Kishimoto, H., Ito, M., Fukunaga, M., Hagino, H., Sone, T., Yoshikawa, H., Nishizawa, Y., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3479 · Cited by 268
Parathyroid hormone: a double-edged sword for bone metabolism
Qin, L., Raggatt, L. J., & Partridge, N. C. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.01.006 · Cited by 263
Burch, J., Rice, S., Yang, H., Neilson, A., Stirk, L., Francis, R., Holloway, P., Selby, P., & Craig, D. (2014) · Health Technology Assessment · doi:10.3310/hta18110 · Cited by 132
Thorsen, K., Kristoffersson, A., Hultdin, J., & Lorentzon, R. (1997) · Calcified Tissue International · doi:10.1007/s002239900179 · Cited by 90
Parathyroid hormone and physical exercise: a brief review.
(2006) · Europe PMC (PubMed Central) · Cited by 63
Metadata
- Authors
- Hodsman, A. B., Fraher, L. J., Ostbye, T., Adachi, J. D., & Steer, B. M.
- Venue
- Journal of Clinical Investigation
- Published
- 1993-03-01
- Volume
- 91
- Issue
- 3
- Pages
- 1138-1148
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2083593344
- Cited by
- 163
- References
- 0
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.